Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Capital Expenditures of $110000.0 for Q1 2026, down 79.82% on a YoY basis from $545000.0 in Q1 2025, and down 93.05% sequentially from $1.6 million in Q4 2025.
Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Capital Expenditures data on file, last reported at $110000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 79.82% year-over-year to $110000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 30.34% YoY), and the FY2025 full-year result was $1.6 million, up 17.34% from the prior year.
- Capital Expenditures declined to $110000.0 in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q4 2025 to a low of -$502000.0 in Q3 2022.
- A 5-year average of $216647.1 and a median of $176000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures surged 2320.0% in 2024 and sank 1439.39% in 2025, its largest moves.
- Tracing PTGX's Capital Expenditures over 5 years: stood at -$42000.0 in 2022, then jumped by 145.24% to $19000.0 in 2023, then jumped by 1531.58% to $310000.0 in 2024, then jumped by 410.32% to $1.6 million in 2025, then plunged by 93.05% to $110000.0 in 2026.
- Business Quant data shows PTGX's Capital Expenditures at $110000.0 in Q1 2026, $1.6 million in Q4 2025, and -$95000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | 110,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 1.58 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | -95,000.00 |
| Sep 30, 2025 | -95,000.00 |
| Jun 30, 2025 | -442,000.00 |
| Jun 30, 2025 | -442,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Dec 31, 2024 | 310,000.00 |
| Dec 31, 2024 | 310,000.00 |
| Sep 30, 2024 | 770,000.00 |
| Sep 30, 2024 | 770,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |